Neurocrine Biosciences, Inc. (NBIX) News
Follow Neurocrine Biosciences, Inc. (NBIX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 38 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
MSCI to Delete Cooper Companies and Neurocrine Biosciences From Global Standard Indexes
EQUITY | Nov 11, 2026, 10:03 PM UTC
M
BeOne Medicines Q3 revenue rises 34%, lifts 2026 outlook
BeOne Medicines reported a 34% rise in Q3 revenue and lifted its 2026 outlook.
EQUITY | Nov 05, 2026, 11:13 AM UTC
M
Neurocrine Biosciences Reports Strong Q3 Results, RBC Says
RBC described Neurocrine Biosciences' Q3 results as strong.
EQUITY | Nov 03, 2026, 04:39 PM UTC
M
Company Reports Fiscal Q3 Profit Up 68.91%
The company reported fiscal 2026 third-quarter profit attributable to shareholders up 68.91% year over year, with basic EPS also reported.
EQUITY | Nov 03, 2026, 05:29 AM UTC
M
Neurocrine raises 2026 sales forecast for movement-disorder drug
Neurocrine shares rise after the company raises its 2026 sales forecast for a movement-disorder drug.
EARNINGS | Nov 02, 2026, 11:03 PM UTC
M
Neurocrine Raises 2026 INGREZZA Sales Guidance to $2.9B–$2.925B
Neurocrine reported third-quarter 2026 revenue of $1.1 billion, up 41% year over year, and raised 2026 INGREZZA net sales guidance to $2.9 billion–$2.925 billion. The prior guidance range was not stated.
EARNINGS | Nov 02, 2026, 10:16 PM UTC
M
Neurocrine Biosciences Announces Q3 2026 Results Release Availability
EQUITY | Nov 02, 2026, 09:59 PM UTC
M
Neurocrine Biosciences Reports Q3 Revenue of $1.12B
Q3 revenue was $1.12 billion, compared with a FactSet estimate of $1.04 billion.
EQUITY | Nov 02, 2026, 09:59 PM UTC
L
Neurocrine Biosciences Reports Q3 EPS of $1.96
EARNINGS | Nov 02, 2026, 09:53 PM UTC
M
Neurocrine Biosciences Reports Q3 Net Income of USD 207 Million
EARNINGS | Nov 02, 2026, 09:51 PM UTC
M
Neurocrine Biosciences Posts Q3 Adjusted EPS of $3.29
Q3 adjusted EPS was $3.29, versus the FactSet estimate of $2.67.
EARNINGS | Nov 02, 2026, 09:51 PM UTC
L
Neurocrine reports third-quarter net income of $206.5 million
EARNINGS | Nov 02, 2026, 09:50 PM UTC
L
Neurocrine Reports Third-Quarter EPS of $1.96
EARNINGS | Nov 02, 2026, 09:50 PM UTC
M
Neurocrine Biosciences Q3 Revenue Rises 41% to $1.12 Billion
Neurocrine reported third-quarter 2026 GAAP net income of $206.5 million and non-GAAP diluted EPS of $3.29. It raised 2026 INGREZZA net sales guidance to $2.90 billion–$2.925 billion.
EQUITY | Nov 02, 2026, 09:40 PM UTC
M
Neurocrine reports lower Q3 net income and higher revenue
EQUITY | Nov 02, 2026, 09:30 PM UTC
M
Nxera Pharma Reports Third-Quarter 2026 Results
Nxera Pharma published operational highlights and consolidated results for the third quarter of 2026.
EQUITY | Oct 30, 2026, 06:38 AM UTC
M
Neurocrine Biosciences Q3 Revenue Estimated
The company is scheduled to report Q3'26 results on November 2 after the market closes. Revenue and EPS estimates were provided.
EQUITY | Oct 26, 2026, 11:00 AM UTC
L
Neurocrine Is Maintained at Buy by UBS
Ratings actions from Benzinga: GMT) Neurocrine Price Target Cut to $214.00/Share From $231.00 by UBSRatings actions from Benzinga
NEWS | Sep 29, 2026, 07:14 PM UTC
L
Eiry W. Roberts named Chief Medical Officer at Neurocrine; Sanjay Keswani to depart
Neurocrine appointed Eiry W. Roberts as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, whose service terminated September 25, 2026.Original SEC Filing: NEUROCRINE BIOSCIENCES INC [ NBIX ]
REGULATION | Sep 28, 2026, 08:27 PM UTC
L
NBIX: AI, China partnerships, and a strong pipeline drive growth amid evolving policy and pricing
China-originated innovation and AI adoption are accelerating development and operational efficiency. INGREZZA and CRENESSITY drive robust growth, while policy changes and new pipeline assets shape future revenue. AI and
GEOPOLITICS | Sep 15, 2026, 04:42 PM UTC
L
NBIX: Biotech growth is driven by innovation, AI adoption, and a diversified, resilient product pipeline
China's innovation is reshaping biotech competition, prompting a focus on speed and selectivity in R&D. AI adoption is driving productivity, while Medicare policy changes will impact pricing in 2029. Growth is supported
GEOPOLITICS | Sep 15, 2026, 04:00 PM UTC
L
NBIX: Multi-product growth, robust pipeline, and strategic adaptation position for long-term success
Expanded from a single to multi-product portfolio with strong sales and a robust pipeline. INGREZZA drives growth with further upside from sales force expansion, while upcoming regulatory changes will impact pricing but
EQUITY | Sep 10, 2026, 02:09 PM UTC
L
NBIX: Multi-product growth, robust pipeline, and strategic pricing drive sustained momentum
The company has evolved into a multi-product, high-growth enterprise with a robust pipeline and strong financials. INGREZZA continues to drive growth, supported by sales force expansion and favorable market dynamics, whi
EQUITY | Sep 10, 2026, 01:42 PM UTC
M
NBIX quarterly revenue hits $1 billion on Ingrezza, CRENESSITY growth
Quarterly revenue reached $1 billion, led by strong growth in Ingrezza, CRENESSITY, and VYKAT XR. Ingrezza remains in double-digit growth; CRENESSITY exceeded expectations with robust adoption and persistency.
EQUITY | Sep 09, 2026, 06:39 PM UTC
M
NBIX quarterly revenue hits $1 billion on Ingrezza, CRENESSITY strength
NBIX reported quarterly revenue of $1 billion, supported by growth in Ingrezza, CRENESSITY and VYKAT XR. The company cited outperforming Ingrezza and CRENESSITY expectations plus pipeline catalysts and commercial initiat
EQUITY | Sep 09, 2026, 06:07 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
L
RBC Capital keeps price target at $198 for Neurocrine
RBC Capital maintained its price target of $198.00 per share on Neurocrine (NBIX).
EQUITY | Sep 08, 2026, 03:07 PM UTC
L
Citigroup raises Neurocrine price target to $253 from $249
Citigroup raised its Neurocrine price target to $253.00 per share from $249.00.
EQUITY | Sep 03, 2026, 04:35 PM UTC
L
NBIX - Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
NBIX - Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 08:01 PM UTC
M
NBIX gets FDA IND acceptance for NBI-1117567 Phase 2 Alzheimer’s cognition
Neurocrine Biosciences, Nxera Pharma’s partner, received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting Alzheimer’s cognition.
EQUITY | Aug 26, 2026, 07:37 AM UTC
M
NBIX: Neurocrine Biosciences Publishes KINECT-PRO Findings
Neurocrine Biosciences publishes KINECT-PRO findings on INGREZZA
EQUITY | Aug 12, 2026, 12:31 PM UTC
H
NBIX Drug Vykat XR Linked to Deaths
NBIX's Vykat XR is linked to deaths and severe side effects, experts warn
EQUITY | Aug 12, 2026, 09:35 AM UTC
H
NBIX Raised to $119.98 at RBC
RBC raises NBIX price target
EQUITY | Jul 31, 2026, 12:12 PM UTC
H
NBIX price target raised to $204
NBIX price target raised to $204 from $200
EQUITY | Jul 31, 2026, 09:45 AM UTC
L
NBIX NBIX - Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
NBIX NBIX - Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
EQUITY | Jul 30, 2026, 08:01 PM UTC
L
NBIX Neurocrine Biosciences RESULTS: Q2, Q2 ADJ EPS $2.85 vs. EST $1.34, Q2 EPS $1.39, Q2 ADJ Net Income $297M vs. EST $141.4M, Q2 Net Incom
NBIX Neurocrine Biosciences RESULTS: Q2, Q2 ADJ EPS $2.85 vs. EST $1.34, Q2 EPS $1.39, Q2 ADJ Net Income $297M vs. EST $141.4M, Q2 Net Income $144M
EARNINGS | Jul 30, 2026, 08:01 PM UTC
L
Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing
() -- Ingrid Delaet, Chief Regulatory Officer, on July 07, 2026, sold 14,571 shares in Neurocrine Biosciences (NBIX) for $2,603,112. Following the Form 4 filing with the SEC, Delaet has control over a total of 16,225 com
REGULATION | Jul 10, 2026, 08:02 AM UTC
L
Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Conge
Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic cong
EQUITY | Jul 01, 2026, 08:08 PM UTC